Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

Published:2018-11 Issue: Volume:103 Page:287
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Choueiri Toni K.,Hessel Colin,Halabi Susan,Sanford Ben,Michaelson M. Dror,Hahn Olwen,Walsh Meghara,Olencki Thomas,Picus Joel,Small Eric J.,Dakhil Shaker,Feldman Darren R.,Mangeshkar Milan,Scheffold Christian,George Daniel,Morris Michael J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastasiertes Nierenzellkarzinom - Erstlinientherapie: Vor- und Nachteile einer Kombinationstherapie berücksichtigen;ASCO und EHA 2023, Urothelkarzinom, Nierenzellkarzinom;2023-08-08

2. Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care);BMJ Open;2023-07

3. Research Progress on Circulating Tumor DNA in Renal Cell Carcinoma;annals of urologic oncology;2023-06-16

4. Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors;Critical Reviews in Oncology/Hematology;2023-01

5. Clinical implications of epigenetics in Renal Cell Carcinoma;Archives of Renal Diseases and Management;2022-07-27